Your browser doesn't support javascript.
loading
Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world.
Watanabe, Ayu; Kamata, Masahiro; Okada, Yoshiki; Suzuki, Shoya; Ito, Makoto; Uchida, Hideaki; Chijiwa, Chika; Egawa, Shota; Hiura, Azusa; Fukaya, Saki; Hayashi, Kotaro; Fukuyasu, Atsuko; Tanaka, Takamitsu; Ishikawa, Takeko; Tada, Yayoi.
Afiliación
  • Watanabe A; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Kamata M; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Okada Y; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Suzuki S; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Ito M; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Uchida H; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Chijiwa C; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Egawa S; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Hiura A; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Fukaya S; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Hayashi K; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Fukuyasu A; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Tanaka T; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Ishikawa T; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Tada Y; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
Exp Dermatol ; 33(9): e15175, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39277874
ABSTRACT
Psossibility and appropriate timing of discontinuation of dupilumab for atopic dermatitis (AD) remain unclear. We explored the possibility of patients, who could maintain remission with topical therapy alone after withdrawing dupilumab in the real world. Furthermore, we identified their characteristics. All adult AD patients who initiated dupilumab from June 2018 to July 2022 and were treated with dupilumab for more than 3 months at our hospital were included in this study. The observation period was from June 2018 to July 2023. In 138 patients, 58 (42.0%) discontinued dupilumab at least once. Among them, 18 (13.0%) discontinued dupilumab but reinitiated dupilumab later due to exacerbation. Only seven patients (5.1%) could maintain remission with topical therapy alone after discontinuation of dupilumab, with characteristics of lower POEM, VAS of pruritus, serum levels of TARC and LDH, and neutrophil counts at baseline, and those of longer duration of dupilumab until its discontinuation (24.0 ± 13.3 vs. 12.8 ± 7.3 months) and lower EASI and affected BSA at the discontinuation of dupilumab. In 118 patients treated with dupilumab for at least 1 year, 38 patients (32.2%) discontinued at least once. Only four patients (3.4%) could maintain remission with topical therapy alone after discontinuation of dupilumab, with characteristics of lower POEM at baseline and lower EASI at the discontinuation of dupilumab. In conclusion, maintaining remission after withdrawing dupilumab is challenging. Discontinuation of dupilumab may be considered in patients with low baseline POEM, after more than 2 years of dupilumab treatment, with a substantial decrease in EASI.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dermatitis Atópica / Anticuerpos Monoclonales Humanizados Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Exp Dermatol Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Dinamarca
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dermatitis Atópica / Anticuerpos Monoclonales Humanizados Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Exp Dermatol Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Dinamarca